| Name | ML218 |
| Description | ML218 is an orally active, selective, potent, and blood-brain barrier-crossing inhibitor of T-type Ca2+ channels (Cav3.1, Cav3.2, Cav3.3) (IC50 for Cav3.2 and Cav3.3 is 310 nM and 270 nM, respectively).ML218 inhibits the burst activity of neurons in the subthalamic nucleus (STN). |
| In vitro | In a voltage clamp experiment, bath application of 3 μM ML218 significantly reduced the T-type Ca2+ current by ∼45%[1]. |
| In vivo | In Male Sprague-Dawley rats (275-299 g) induced by haloperidol,ML218 (0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg; Oral administration; once) treatment reversed cataleptic behavior in rats induced by a 0.75 mg/kg dose of haloperidol[1]. |
| Storage | Store at low temperature
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+90% Corn Oil : 5 mg/mL (13.54 mM), Sonication is recommended.
DMSO : 100 mg/mL (270.76 mM), Sonication is recommended.
|
| Keywords | ML-218 | ML218 | ML 218 | Cav3.3 | Cav3.2 | CalciumChannel | Calcium Channel | Ca2+ flux |
| Inhibitors Related | Quadrol | Tricaine methanesulfonate | Nisoldipine | 2,4,6-Tri-tert-butylphenol | Chlorocresol | L-Ascorbic acid | L-Phenylalanine | L-Ascorbic acid sodium salt | 2-Nitrobenzoic acid | Magnesium Chloride Hexahydrate | Magnesium sulfate | Cinchonine |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Calcium Channel Compound Library | Anti-Cardiovascular Disease Compound Library | Bioactive Compounds Library Max | Ion Channel Targeted Library |
United States
